A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis

A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis

Purpose: Interleukin (IL)-17 and IL-23 inhibitors are the newest biologic agents used in the management of moderate-to-severe psoriasis. Active comparator studies allow for direct comparison of different biologic agents. We sought to systematically investigate the efficacy of newer biologic agents c...

Full description

Bibliographic Details
Main Authors: Daniel J. No, Mina Amin, Tina Bhutani, Jashin J. Wu
Format: Article
Language:English
Published: Taylor & Francis Group 2018-07-01
Series:Journal of Dermatological Treatment
Subjects:
biologic
comparative study
tumor necrosis factor inhibitor
interleukin 17
interleukin 23
efficacy
Online Access:http://dx.doi.org/10.1080/09546634.2017.1402116

Internet

http://dx.doi.org/10.1080/09546634.2017.1402116

Similar Items